Skip to main content

Find a clinical trial

AV-951-15-303

A Phase 3, Randomized, Controlled, Multi-Center, Open-Label Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma Nieves Martinez Chanza

AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

Sevrage Tabagique

Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomized study

CLEAR

A Multicenter, Open-Label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR) Spyridon Sideris

AURA

Avelumab as neoadjuvant therapy in subjects with urothelial muscle invasive bladder cancers Thierry Gil

Intervention destinée aux parents

L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité

IJB_2691

Phase 3 Randomized Study Comparing Nivolumab and Ipilimumab Combination vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse Spyridon Sideris

IJB_2728

Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention

OX2016-203-01

An open-label, dose-escalation, phase I study to assess the safety, pharmacokinetics and pharmacodynamics of AsiDNA, a DNA repair inhibitor administered intravenously in patients with advanced solid tumors Nuria Kotecki

MK-3475-012

A phase Ib multi-cohort study of MK-3475 in subjects with advanced solid tumors Ahmad Hussein Awada

METASUN UCL-ONCO 2012-09

A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma Thierry Gil

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

WO29636

WO29636 A Phase III, Open-Label, Multicenter, Randomized Study Of Atezolizumab (Anti?Pd-L1 Antibody) Versus Observation As Adjuvant Therapy In Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection Spyridon Sideris

I7W-MC-JQBA

A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Ahmad Hussein Awada

DANUBE

A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Bladder Cancer Thierry Gil

GO29674

A Phase Ib, Open-Label, Dose-escalation Study of the safety and Pharmacokinetics of MOXR0916 and MPDL3280A in Patients with Locally Advanced or Metastatic Solid Tumors Ahmad Hussein Awada

PEACE V - STORM

PEACE V: A randomized phase II trial for the Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) François-Xavier Otte

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

IJB-MULTI-MIME-A-2017

IJB-MULTI-MIME-A-2017 Multiorgan Metabolic imaging response assessment of Abemaciclib: the MiMe-A trial Alain Hendlisz

IMBrella

An open label, multicenter extension study in patients previously enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd sponsored atezolizumab study (IMBRELLA B) Ahmad Hussein Awada